Special USA Newsletter January 2025 |
| |
|
|
---|
|
EDITORIAL BY PATRICK ALEXANDRE, FOUNDER & CEO |
|
|
---|
|
| In the product launch phase, the American market is essential for any pharmaceutical laboratory. Combining a market potential comparable to Europe in volume, higher average prices, and a unified geography, the United States offers the advantage of accelerated production cost recovery. For CROSSJECT, there is also the BARDA contract*, which is the first confirmed order for ZEPIZURE®. While attractive, the American market requires a patient, rigorous approach tailored to local diagnostic, prescription, and commercial practices. That’s why CROSSJECT is building a local team to support its growth in the United States. |
|
---|
|
CROSSJECT’s development in the United States |
|
|
---|
|
| As CROSSJECT prepares for the launch of ZEPIZURE® in the U.S. market, Tony TIPTON (Chief Operating Officer), Baya FODIL (Global Vice President of Marketing & Sales), and Dan CHICHE (Clinical Research and Medical Affairs) share their perspectives, challenges, and opportunities tied to this launch, which marks a strategic transition for CROSSJECT. |
Tony TIPTON How are you approaching the launch of CROSSJECT and ZEPIZURE®, its first product in the United States? The year 2025 will undoubtedly be exciting and pivotal for our company. It will signify our transition from a manufacturing entity to a specialized pharmaceutical company integrating manufacturing and commercialization. As a broad overview, our commercial efforts will focus on awareness, education and influencing our various customer types. My experience has taught me to approach commercialization through five key phases: evaluation, analysis, strategy development, preparation, and execution. These phases align with the schedule for our submissions to the FDA (Food and Drug Administration) and potential approval dates. Decisions made in one phase naturally influence the subsequent steps. |
|
---|
|
Tony TIPTON, Chief Operating Officer USA |
|
|
---|
|
New Webiste Our status as a pharmaceutical laboratory and our strong commercial ambitions will be more effectively supported by a modernized design and updated content, accessible in both French and English. www.crossject.com | JP Morgan Healthcare Conference 2025 This annual event, which brings together investors, distributors, and service providers, allowed us to establish valuable connections for the development of our U.S. presence. | 🗓️ International Agenda The coming months will be busy for CROSSJECT’s team, which will be attending numerous events: - Biomed Event à Paris - February 2025
- European MidCap Event – Francfort - February 2025
- AAAAI/WAO Joint Congress - San Diego – February 2025
- DCAT Week - New York - March 2025
- SmallCap Event - Paris – March 2025
- INVESTOR ACCESS – Paris – April 2025
- CPhI North America - Philadelphie - May 2025
- BIO International Convention Boston – June 2025
To schedule a meeting: |
|
|
---|
|
| |
| | |
| |
---|
|
|
|
|
---|
|
CROSSJECT Vous avez reçu cet e-mail parce que vous vous êtes inscrit à notre newsletter. Se désinscrire |
|
---|
|
|
|